ЗЕЛЕНЫЙ СИНТЕЗ ЗОЛОТЫХ НАНОЧАСТИЦ С СИЛИМАРИНОМ, ИХ ДЕЙСТВИЕ НА КУЛЬТУРАХ КЛЕТОК ЖИВОТНЫХ
Ключевые слова:
золотые наночастицы, наноматериалы, силимарин, флавоноидыАннотация
Синтезированы золотые наночастицы с использованием силимарина – экстракта Silybum marianum. Используя электронную микроскопию и метод динамического светорассеяния, был проведен анализ препарата. Препарат концентрировали лиофилизировальной сушкой и изучали активность его растворенной формы на культурах клеток животных – здоровых и опухолевых.
Скачивания
Данные скачивания пока недоступны.
Библиографические ссылки
1. Pollastri S., Tattini M. Flavonols: old compounds for old roles // Ann. Bot., 2011., 108., P. 1225–1233.
2. Wagner H., Horhammer L., Munster R. On the chemistry of silymarin (silibinin), the active principle of the fruits of Silybum marianum L. Gaertn. (Carduus marianus L.) // Arzneimittelforschung, 1968, 18, P. 688–696.
3. Wagner H., Diesel P., Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. // Arzneimittelforschung, 1974, 24, P. 466–471.
4. Sonnenbichler J., Zetl I. Biochemical effects of the flavonolignan silibinin on RNA, protein, and DNA synthesis in rat liver // Progr. Clin. Biol. Res. 1986. 213. 319–331.
5. Morazzoni P., Bombardelli E. Silybum marianum (Carduus marianus) // Fitoterapia, 1996, 66, P. 3–42.
6. Wellington K., Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders // BioDrugs, 2001, 15, P. 465–489.
7. Tasduq S.A., Peerzada K., Koul S., Bhat R., Johri R.K.Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin // Hepatol, Res., 2005, 31. P.132–135.
8. Wagner H. Plant constituents with antihepatotoxic activity. In: Beal J.L., Reinhard E. eds. Natural Products as Medicinal Agents. Stuttgart: Hippokrates-Verlag; 1981.
9. Wattenberg L.W. An overview of chemoprevention: current status and future prospects // Proc. Soc. Exp. Biol. Med., 1997, 216, P. 133–141.
10. Dragsted L.O. Natural antioxidants in chemoprevention // Arch. Toxicol. Suppl., 1998., 20., P. 209–226.
11. Lah J.J., Cui W., Hu K.Q. Effects and mechanisms of silibinin on human hepatoma cell lines // World J. Gastroenterol, 2007, 13, P. 5299–5305.
12. Cui W., Gu F., Hu K.Q. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice // World J. Gastroenterol, 2009, 15, P. 1943–1950.
13. Mateen S., Raina K., Jain A., Agarwal C., Chan D., Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells // Epigenetics, 2012, 7, P. 1161–1172.
14. Kauntz H., Bousserouel S., Gosse?F., Raul F. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells // Apoptosis, 2011, 16, P. 1042–1053.
15. Gaz?k R., Walterova D., Kren V. Silybin and silymarin – new and emerging applications in medicine // Curr. Med. Chem, 2007, 14, P. 315–338.
16. Singh R., Lillard J.W. Jr. Nanoparticle-based targeted drug delivery // Exp. Mol. Pathol. 2009. 86. 215–223.
17. Sundar S., Prajapati V.K. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules // Curr. Med. Chem., 2012, 19, P. 3196–3202.
18. Khlebtsov N.G., Dykman L.A. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies // Chem. Soc. Rev., 2011, 40, P. 1647–1671.
19. Dykman L.A., Khlebtsov N.G. Gold nanoparticles in biomedical applications: recent advances and perspectives // Chem. Soc. Rev., 2012, 41, P. 2256–2282.
20. Yen H.J., Hsu S.H., Tsai C.L. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes // Small. 2009. 5. 1553–1561.
21. Dykman L.A., Staroverov S.A., Bogatyrev V.A., Shchyogolev S.Yu. Gold nanoparticles as an antigen carrier and an adjuvant. -New York: Nova Science Publishers, 2010, 54 p.
22. Dykman L.A., Khlebtsov N.G. Uptake of engineered gold nanoparticles into mammalian cells // Chem. Rev., 2014, 114, P. 1258–1288.
23. Khlebtsov N., Bogatyrev V., Dykman L., Khlebtsov B., Staroverov S., Shirokov A., Matora L., Khanadeev V., Pylaev T., Tsyganova N., Terentyuk G. Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites // Theranostics, 2013, 3, P. 167–180.
24. Kabir N., Ali H., Ateeq M., Bertino M.F., Shah M.R., Franze L. Silymarin coated gold nanoparticles ameliorates CCl4-induced hepatic injury and cirrhosis through down regulation of Hepatic stellate cells and attenuation of Kupffer cells // RSC Adv., 2014, 4, P. 9012–9020.
25. Khlebtsov N.G., Dykman L.A. Optical properties and biomedical applications of plasmonic nanoparticles // J. Quant. Spectrosc. Radiat. Transfer., 2010, 111., P. 1–35.
26.Oez S., Platzer E., Welte K. A quantitative colorimetric method to evaluate the functional state of human polymorphonuclear leukocytes // Blut, 1990, 60, P. 97– 102.
2. Wagner H., Horhammer L., Munster R. On the chemistry of silymarin (silibinin), the active principle of the fruits of Silybum marianum L. Gaertn. (Carduus marianus L.) // Arzneimittelforschung, 1968, 18, P. 688–696.
3. Wagner H., Diesel P., Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. // Arzneimittelforschung, 1974, 24, P. 466–471.
4. Sonnenbichler J., Zetl I. Biochemical effects of the flavonolignan silibinin on RNA, protein, and DNA synthesis in rat liver // Progr. Clin. Biol. Res. 1986. 213. 319–331.
5. Morazzoni P., Bombardelli E. Silybum marianum (Carduus marianus) // Fitoterapia, 1996, 66, P. 3–42.
6. Wellington K., Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders // BioDrugs, 2001, 15, P. 465–489.
7. Tasduq S.A., Peerzada K., Koul S., Bhat R., Johri R.K.Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin // Hepatol, Res., 2005, 31. P.132–135.
8. Wagner H. Plant constituents with antihepatotoxic activity. In: Beal J.L., Reinhard E. eds. Natural Products as Medicinal Agents. Stuttgart: Hippokrates-Verlag; 1981.
9. Wattenberg L.W. An overview of chemoprevention: current status and future prospects // Proc. Soc. Exp. Biol. Med., 1997, 216, P. 133–141.
10. Dragsted L.O. Natural antioxidants in chemoprevention // Arch. Toxicol. Suppl., 1998., 20., P. 209–226.
11. Lah J.J., Cui W., Hu K.Q. Effects and mechanisms of silibinin on human hepatoma cell lines // World J. Gastroenterol, 2007, 13, P. 5299–5305.
12. Cui W., Gu F., Hu K.Q. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice // World J. Gastroenterol, 2009, 15, P. 1943–1950.
13. Mateen S., Raina K., Jain A., Agarwal C., Chan D., Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells // Epigenetics, 2012, 7, P. 1161–1172.
14. Kauntz H., Bousserouel S., Gosse?F., Raul F. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells // Apoptosis, 2011, 16, P. 1042–1053.
15. Gaz?k R., Walterova D., Kren V. Silybin and silymarin – new and emerging applications in medicine // Curr. Med. Chem, 2007, 14, P. 315–338.
16. Singh R., Lillard J.W. Jr. Nanoparticle-based targeted drug delivery // Exp. Mol. Pathol. 2009. 86. 215–223.
17. Sundar S., Prajapati V.K. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules // Curr. Med. Chem., 2012, 19, P. 3196–3202.
18. Khlebtsov N.G., Dykman L.A. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies // Chem. Soc. Rev., 2011, 40, P. 1647–1671.
19. Dykman L.A., Khlebtsov N.G. Gold nanoparticles in biomedical applications: recent advances and perspectives // Chem. Soc. Rev., 2012, 41, P. 2256–2282.
20. Yen H.J., Hsu S.H., Tsai C.L. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes // Small. 2009. 5. 1553–1561.
21. Dykman L.A., Staroverov S.A., Bogatyrev V.A., Shchyogolev S.Yu. Gold nanoparticles as an antigen carrier and an adjuvant. -New York: Nova Science Publishers, 2010, 54 p.
22. Dykman L.A., Khlebtsov N.G. Uptake of engineered gold nanoparticles into mammalian cells // Chem. Rev., 2014, 114, P. 1258–1288.
23. Khlebtsov N., Bogatyrev V., Dykman L., Khlebtsov B., Staroverov S., Shirokov A., Matora L., Khanadeev V., Pylaev T., Tsyganova N., Terentyuk G. Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites // Theranostics, 2013, 3, P. 167–180.
24. Kabir N., Ali H., Ateeq M., Bertino M.F., Shah M.R., Franze L. Silymarin coated gold nanoparticles ameliorates CCl4-induced hepatic injury and cirrhosis through down regulation of Hepatic stellate cells and attenuation of Kupffer cells // RSC Adv., 2014, 4, P. 9012–9020.
25. Khlebtsov N.G., Dykman L.A. Optical properties and biomedical applications of plasmonic nanoparticles // J. Quant. Spectrosc. Radiat. Transfer., 2010, 111., P. 1–35.
26.Oez S., Platzer E., Welte K. A quantitative colorimetric method to evaluate the functional state of human polymorphonuclear leukocytes // Blut, 1990, 60, P. 97– 102.
